Skip to main content

Table 2 Results

From: Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States

Summary of results

Ceftolozane/tazobactam + metronidazole

Piperacillin/tazobactam

Incremental Ceftolozane/tazobactam + metronidazole - Piperacillin/tazobactam

Total costs per patient

$44,226

$44,811

-$585

Total life years per patient (undiscounted)

21.75

21.50

0.25

Total QALYs per patient (undiscounted)

18.49

18.27

0.22

Total QALYs per patient (discounted)

12.85

12.70

0.15

Incremental Cost Effectiveness Ratio (Cost per discounted QALY saved)

Dominant

Hospitalization days saved per-patient

0.63

Distribution of patients based on empiric treatment

   

 Resistant to initial therapy (%)

35.2

48.8

 Susceptible to initial therapy (%)

64.8

51.2

Costs

   

 Hospital costs per patient

$15,468

$17,069

-$1601

 Drug costs per patient

$818

$196

$622

 Lifetime health care expenditure per patient

$27,940

$27,546

$394

  1. QALY Quality Adjusted Life Year, IAAT Initial appropriate antibiotic therapy, IIAT Initial inappropriate antibiotic therapy